As of Friday close, Sanofi’s (NASDAQ:SNY) stock was up $0.32, moving up 0.60 percent to $53.25. The average number of shares traded per day over the past five days has been 954,620 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.28 fall in that time frame. In the last twenty days, the average volume was 1,387,450, while in the previous 50 days, it was 1,230,686.
Since last month, SNY stock retreated -2.69%. Shares of the company fell to $49.97 on 08/03/23, the lowest level in the past month. A 52-week high of $57.82 was reached on 04/26/23 after having rallying from a 52-week low of $36.91. Since the beginning of this year, SNY’s stock price has risen by 9.95% or $4.82, and marked a new high 18 times. However, the stock has declined by -7.90% since its 52-week high.
Valuation Metrics
Right now, Sanofi (SNY) has a P/E ratio of about 14.15. The stock’s beta is 0.56. Besides these, the trailing price-to-sales (P/S) ratio of 2.67, the price-to-book (PB) ratio of 1.67.
The latest dividend of $1.3770 per share was paid out, which is -23.36% less than last year’s $1.7968. On Tuesday May 30 2023, a $0.4198 dividend decrease was announced.
Financial Health
In the three months ended June 29, Sanofi’s quick ratio stood at 0.80, while its current ratio was 1.20, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.23, and the total debt-to-equity ratio was 0.29. On the profitability front, the trailing twelve-month gross margin is 69.80% percent. Based on annual data, SNY earned $33.39 billion in gross profit and brought in $47.82 billion in revenue.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. SNY’s revenue rose 17.67% during the quarter, while net income inched up to $50.84 billion. While analysts expected Sanofi to report $1.55 quarterly earnings, the actual figure was $0.95 per share, beating the consensus estimate by -38.70%. During the quarter, the company generated $2.04 billion in EBITDA. The liabilities of Sanofi were 57.14 billion at the end of its most recent quarter ended June 29, and its total debt was $21.03 billion.
Technical Picture
This quick technical analysis looks at Sanofi’s (SNY) price momentum. With a historical volatility rate of 12.41%, the RSI 9-day stood at 54.55% on 18 August.
With respect to its five-day moving average, the current Sanofi price is down by -0.52% percent or -$0.28. At present, SNY shares trade -3.09% below its 20-day simple moving average and +0.06% percent above its 100-day simple moving average. However, the stock is currently trading approximately +4.66% above its SMA50 and +23.18% above its SMA200.
Stochastic coefficient K was 71.88% and Stochastic coefficient D was 70.36%, while ATR was 0.77. Given the Stochastic reading of 81.39% for the 14-day period, the RSI (14) reading has been calculated as 52.79%. As of today, the MACD Oscillator reading stands at -0.22, while the 14-day reading stands at 0.23.
Analyst Ratings
HSBC Securities launched its rating on Sanofi (NASDAQ: SNY) to a Buy in a note to investors on July 14, 2023. Sanofi (SNY) has been rated Overweight by analysts. According to 2 brokerage firms, SNY is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 4 analysts rate Sanofi stock as buy, with 12 recommending it as overweight.
With a median target price of $62.00, the current consensus forecast for the stock is $49.66 – $75.73. Based on these forecasts, analysts predict Sanofi (SNY) will achieve an average price target of $61.42.
